Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1912779 | 0.95 | BRD4 (0.32) | EGFRALDH1A1GAAHPGDMAPT | |
| SCHEMBL427425 | 0.86 | — | — | |
| SCHEMBL7932132 | 0.77 | BRD4 (0.31) | — | |
| SCHEMBL7933899 | 0.73 | EGFR (0.34) | EGFRALDH1A1GAANPC1HPGD | |
| SCHEMBL1191143 | 0.72 | BRD4 (0.34) | ALDH1A1HPGD | |
| SCHEMBL8989855 | 0.71 | — | — | |
| SCHEMBL12871708 | 0.70 | ELANE (0.36) | EGFRALDH1A1GAAHPGDMAPT | |
| SCHEMBL10881461 | 0.68 | ALDH1A1 (0.32) | EGFRALDH1A1GAAHPGDRAB9A | |
| SCHEMBL19846937 | 0.68 | TP53 (0.31) | EGFRALDH1A1GAAHPGDMAPT | |
| SCHEMBL12871718 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6316634-B2 | REACTING 3-ALKOXY/HYDROXY-2-HALO-CYCLOHEPTEN-1-ONE WITH ALKYLAMINIDINE HALIDE TO FORM CYCLOHEPTIMIDAZOLE COMPOUND | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6278027-B1 | AS CHEMICAL INTERMEDIATES IN PREPARATION OF DRUGS SUCH AS CYCLOHEPTIMIDAZOLE DERIVATIVES | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2001-08-21 | — | — | US | disclosed |
| US-20010008944-A1 | Method for preparing cycloheptimidazoles | TOMIYAMA TSUYOSHI (JP) | 2001-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008944-A1 | Method for preparing cycloheptimidazoles | DHFR, DHPS, MTHFD1 | EGFR 3448/4885ALDH1A1 465/4885GAA 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.